Department of Pharma invites fresh applications under PLI scheme for bulk drugs
New Delhi: The Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers has invited applications from the Active Pharmaceutical Ingredients (API) manufacturers and eligible industries under the Production Linked Incentive (PLI) scheme for bulk drugs.
The invited applications are for the eligible products under the PLI Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and APIs in the country.
The department is seeking applications for several unsubscribed or partially subscribed products. These include important fermentation and chemical synthesis-based drugs such as Erythromycin Thiocyanate, Neomycin, Gentamycin, Clindamycin Base, Streptomycin, Tetracycline, among others.
Each eligible product comes with a set minimum annual production capacity and a maximum number of applicants that can be selected. For instance, up to two applicants will be selected for products like Gentamycin and Neomycin, while four manufacturers can apply for Ciprofloxacin and 2-Methyl (5) Nitro Imidazole.
Applicants must meet key conditions of the scheme, such as allocation according to available capacities, incentive ceiling in respect of products and limit of incentive up to the production tenure, i.e., up to FY 2027-28 for chemical synthesis products and up to FY 2028-29 for fermentation-based products.
Further, applicants or their group companies, including subsidiaries who had applied earlier under the scheme for the said unsubscribed and partially subscribed products and were granted approval, but who subsequently withdrew from the scheme or whose approval was cancelled in line with clause 12.11 of the scheme guidelines or owing to nonperformance, are not eligible to apply for the same eligible product.
Accordingly, applications are invited for the following eligible products:
| S. No. | Target segment | Name of eligible product | Minimum annual production capacity as per scheme guidelines (in MT) | Total available production capacity (in MT) | Maximum no. of applicants to be selected |
| 1 | Key Fermentation based KSMs/Drug Intermediates | Erythromycin Thiocyanate (TIOC) | 800 | 1600 | 2 |
| 2 | Fermentation based niche KSMs/Drug Intermediates/APIs | Neomycin | 80 | 160 | 2 |
| 3 | Fermentation based niche KSMs/Drug Intermediates/APIs | Gentamycin | 40 | 80 | 2 |
| 4 | Fermentation based niche KSMs/Drug Intermediates/APIs | Clindamycin Base | 60 | 120 | 2 |
| 5 | Fermentation based niche KSMs/Drug Intermediates/APIs | Streptomycin | 50 | 100 | 2 |
| 6 | Fermentation based niche KSMs/Drug Intermediates/APIs | Tetracycline | 200 | 400 | 2 |
| 7 | Key Chemical Synthesis based KSMs/Drug Intermediates | 2-Methyl (5) Nitro Imidazole (2MNI) | 800 | 3200 | 4 |
| 8 | Other Chemical Synthesis based KSMs/Drug Intermediates/APIs | Ciprofloxacin | 150 | 600 | 4 |
| 9 | Other Chemical Synthesis based KSMs/Drug Intermediates/APIs | Diclofenac Sodium | 175 | 175 | 1 |
| 10 | Key Chemical Synthesis based KSMs/Drug Intermediates | Dicyandiamide (DCDA) | 8000 | 24000 | 3 |
| 11 | Key Chemical Synthesis based KSMs/Drug Intermediates | 1,1 Cyclohexane Diacetic Acid (CDA) | 1500 | 1500 | 1 |
The eligible applicants may apply through online mode only (https://plibulkdrugs.ifciltd.com) from 15.05.2025 to 14.06.2025. Detailed guidelines of the scheme and necessary corrigendum are available at https://pharma-dept.gov.in/schemes.
The last date of receipt of complete application is 14.06.2025.
For more details, check out the full story on the link mentioned below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.